<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        36-590-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYTERO PLUS 12.5 mg/ 1000 mg Film Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE,ALOGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        117.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Takeda Pharmaceutical Company Limited, Osaka Plant " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Takeda Pharmaceutical Company Limited, Osaka Plant 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Zytero Plus is<br />Zytero Plus contains two different medicines called alogliptin and metformin in one tablet:<br />- alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). Alogliptin works to increase the levels of insulin in the body after a meal and decrease the amount of sugar in the body.<br />- metformin belongs to a group of medicines called biguanides which also help to lower blood sugar by lowering the amount of sugar made in the liver and helping insulin to work more effectively.</p><p>What Zytero Plus is used for<br /> ZYTERO PLUS contains 2 prescription diabetes medicines, alogliptin (VIPIDIA) and metformin hydrochloride.<br /> ZYTERO PLUS is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes.<br /> ZYTERO PLUS is not for people with type 1 diabetes.<br /> ZYTERO PLUS is not for people with diabetic ketoacidosis (increased ketones in blood or urine). It is not known if ZYTERO PLUS is safe and effective in children under the age of 18.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Plus Do NOT take Zytero Plus :<br /> if you are allergic to alogliptin, metformin or any of the other ingredients of this medicine (listed<br />in section 6)<br /> if you have had a serious allergic reaction to any other similar medications that you take to control your blood sugar. Symptoms of a serious allergic reaction may include; rash, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing<br /> if you recently had a heart attack or have severe circulatory problems including shock<br /> if you have severe breathing difficulties<br /> if you have liver disease<br /> if you have moderate or severe kidney disease<br /> if you drink alcohol excessively (either every day or in large quantities only from time to time)<br /> if you have diabetic ketoacidosis (a serious complication of poorly controlled diabetes). Symptoms include excessive thirst, frequent urination, loss of appetite, nausea or vomiting and rapid weight loss<br /> if you have a severe infection or are seriously dehydrated (have lost a lot of water from your body)<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Zytero Plus :<br /> if you have type 1 diabetes (your body does not produce insulin).</p><p> if you are taking Zytero Plus with insulin or a thiazolidinedione. Your doctor may want to reduce your dose of insulin or a thiazolidinedione when you take it together with Zytero Plus in order to avoid too low blood sugar (hypoglycaemia).<br /> if you are taking another medicine for diabetes that contains a &ldquo;sulphonylurea&rdquo;, you should not start taking Zytero Plus .<br /> if you are going to have an operation under general, spinal or epidural anaesthetic. You may be advised to stop taking this medicine for some time before and after the procedure.<br /> if you have had allergic reactions to any other medications that you take to control your blood sugar. Symptoms may include general itching and feeling of heat especially affecting the scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson syndrome)<br /> if you have or have had a disease of the pancreas<br />During treatment with Zytero Plus , your doctor will check your kidney function at least once a year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening.<br />Children and adolescents<br />Zytero Plus is not recommended for children and adolescents under 18 years due to the lack of data in these patients.<br />Other medicines and Zytero Plus<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following:<br /> hydrocortisone and prednisolone (corticosteroids) used to treat diseases that involve inflammation like asthma and arthritis</p><p> cimetidine, used to treat stomach problems<br /> bronchodilators (beta-2 agonists) which are used to treat asthma<br /> ramipril, lisinopril and enalapril (ACE inhibitors) used to treat high blood pressure<br /> water tablets (diuretics) which increase urine production<br /> iodinated contrast agents used in taking X-rays<br /> medicines containing alcohol<br />Zytero Plus with alcohol<br />Do not take this medicine with excessive amounts of alcohol as you could be at greater risk of developing lactic acidosis, a serious complication which must be treated in a hospital (see section 4 &lsquo;Possible side effects&rsquo;).<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use Zytero Plus if you are pregnant.<br />Zytero Plus is not recommended during breast-feeding since metformin passes into breast milk.<br />Driving and using machines<br />Zytero Plus is not known to affect your ability to drive and use machines. Taking Zytero Plus in combination with medicines called pioglitazone or insulin can cause too low blood sugar levels (hypoglycaemia), which may affect your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p> Take ZYTERO PLUS exactly as your doctor tells you to take it.<br /> Take ZYTERO PLUS 2 times each day.<br /> Take ZYTERO PLUS with food to lower your chances of having an upset stomach.<br /> Do not break or cut ZYTERO PLUS tablets before swallowing.<br /> Your doctor may need to change your dose of ZYTERO PLUS to control your blood glucose. Do not change your dose unless told to do so by your doctor.<br /> If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose, and take the next dose at your regular schedule. Do not take 2 doses of ZYTERO PLUS at the same time.<br /> If you take too much ZYTERO PLUS , call your doctor or go to the nearest hospital emergency room right away.<br /> If your body is under stress, such as from fever, infection, accident or surgery, the dose of your diabetes medicines may need to be changed. Call your doctor right away.<br /> Stay on your diet and exercise programs and check your blood sugar as your doctor tells you to.<br /> Your doctor may do certain blood tests before you start ZYTERO PLUS and during treatment as needed. Your doctor may ask you to stop taking ZYTERO PLUS based on the results of your blood tests due to how well your kidneys are working.</p><p> Your doctor will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.<br />If you take more Zytero Plus than you should<br />If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away. Take this leaflet or some tablets with you so that your doctor knows exactly what you have taken.<br />If you forget to take Zytero Plus<br />If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Zytero Plus<br />Do not stop taking Zytero Plus without consulting your doctor first. Your blood sugar levels may increase when you stop taking Zytero Plus .<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />STOP taking Zytero Plus and contact a doctor immediately if you notice any of the following serious side effects:<br />Very rare (may affect less than 1 in 10,000 people):<br /> Lactic acidosis (a build-up of lactic acid in the blood). Lactic acidosis is a medical emergency and must be treated in a hospital. It can particularly affect patients whose kidneys are not working properly. Symptoms include some or all of the following: feeling cold or uncomfortable, severe nausea with or without vomiting, unexplained weight loss, or rapid breathing.<br />Not known (frequency cannot be estimated from the available data):<br /> An allergic reaction. The symptoms may include: a rash, hives, swallowing or breathing problems, swelling of your lips, face, throat or tongue and feeling faint.<br /> A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme).<br /> Severe and persistent pain in the abdomen (stomach area) which might reach through to your back as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).<br />You should also discuss with your doctor if you experience the following side effects:<br />Very common (may affect more than 1 in 10 people):<br /> Stomach ache<br /> Diarrhoea</p><p> Loss of appetite<br /> Feeling sick</p><p> Being sick.<br />Common (may affect up to 1 in 10 people):<br /> Symptoms of low blood sugar (hypoglycaemia) may occur when Zytero Plus is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide). Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change or feeling confused. Your blood sugar could fall below the normal level, but can be increased again by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.<br /> Cold symptoms such as sore throat, stuffy or blocked nose, feeling tired, fever, chills, dry cough<br /> Rash<br /> Itchy skin with or without hives<br /> Headache<br /> Indigestion, heartburn<br /> Vomiting and/or diarrhoea<br />Very rare:<br /> Decreased vitamin B12 levels or anaemia; symptoms include tiredness, lethargy, feeling faint, becoming breathless<br /> Liver problems (hepatitis).</p><p>Not known:<br /> Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness, loss of appetite, dark urine or yellowing of your skin or the whites of your eyes.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC) listed at the end of this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30 &deg;C.<br />Keep the container of ZYTERO PLUS tightly closed. Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Zytero Plus contains<br />- The active substances are alogliptin and metformin hydrochloride.<br />Each 12.5 mg/500 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 500 mg metformin hydrochloride.<br />Each 12.5 mg/1000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 1000 mg metformin hydrochloride.<br />The other ingredients are mannitol, microcrystalline cellulose, povidone, crospovidone and magnesium stearate; the tablets are film-coated with hypromellose 2910, talc, titanium dioxide and ferric oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ZYTERO PLUS tablets are available in the following strengths and packages:
12.5mg+500mg tablet: Pale yellow, oblong , biconvex, film-coated tablet with “12.5/500” debossed on one side and “322M” debossed on the other side.
12.5 mg+1000mg tablet: Pale yellow, oblong ,biconvex, film-coated tablet with “12.5/1000” debossed on one side and “322M” debossed on the other side
ZYTERO PLUS is available in a pack size of 56 tablets (8 blisters each containing 7 tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder, secondary packaging and final release site:<br />Batterjee pharmaceutical factory Industrial Area-phase-IV,<br />Jeddah-21443, Kingdom of Saudi<br />Bulk manufacturing site:<br />Takeda Pharmaceutical Company Limited 17-85, Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan</p><p>Primary Packaging site: Packaging Coordinators, LLC 2200 Lake Shore Drive, Woodstock, IL 60098, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما ھو زایتیرو بلاس<br />یحتوي زایتیرو بلاس على نوعین مختلفین من الأدویة المسماة ألوجلیبتین ومیتفورمین في قرص واحد:<br />یعمل الألوجلیبتین على زیادة .(DPP-4) - ینتمي الألوجلیبتین إلى مجموعة من الأدویة تسمى مثبطات بیبتیدیز ثنائي البیبتیدیل- ٤<br />معدلات الأنسولین في الجسم بعد تناول الوجبة وتقلیل كمیة السكر في الجسم.<br />- ینتمي المیتفورمین إلى مجموعة من الأدویة تسمى بیجوانایدز وھي تساعد أیضا على تخفیض سكر الدم عن طریق تخفیض كمیة<br />السكر التي یتم تصنیعھا في الكبد ومساعدة الأنسولین على العمل بكفاءة أكبر.</p><p>وتعد كلا مجموعتي الأدویة &quot;مضادات سكر فمویة&quot;.<br />فیم یستخدم زایتیرو بلاس ؟<br />&bull;<br />یحتوي زایتیرو بلاس على دواءین لعلاج السكري وھما: الألوجلیبتین (ڤیبدیا) و میتفورمین ھیدروكلورید.<br />زایتیرو بلاس ھو عقار یُوصف بواسطة الطبیب ویستخدم مع النظام الغذائي والتمارین لتحسین السیطرة على مستوى السكر في<br />&bull;<br />. الدم (الجلوكوز) في البالغین المصابین بمرض السكري من النوع ۲<br />. زایتیرو بلاس غیر مخصص للأشخاص الذین یعانون من مرض السكري من النوع ۱<br />&bull; زایتیرو بلاس غیر مخصص للأشخاص الذین یعانون من الحماض الكیتوني السكري (ارتفاع مستوى الكیتونات في الدم أو<br />البول).<br />من غیر المعروف إذا ما كان زایتیرو بلاس آمن اً وفعالا للاستخدام في الأطفال الأصغر سناً من ۱۸ عام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول زایتیرو بلاس:<br />.( &bull; إذا كنت مصاباً بالحساسیة للألوجلیبتین أو المیتفورمین أو أي من المكونات الأخرى لھذا العقار (المدرجة بالقسم ٦<br />&bull; إذا كنت قد أصبت برد فعل تحسسي (تفاعل آرجي) خطیر لأي من العقاقیر الأخرى المماثلة التي تساعد في السیطرة على<br />مستوى السكر بدمك. وقد تشمل أعراض التفاعل الآرجي الحاد: الطفح الجلدي والبقع الحمراء البارزة على جلدك (الشرى)<br />وتورم الوجھ والشفاه واللسان والحلق الذي قد یسبب ضیق بالتنفس أو صعوبة بالبلع.<br />&bull; إذا أصبت بنوبة قلبیة أو مشاكل وعائیة حادة مؤخراً، بما في ذلك الصدمة.<br />&bull; إذا كانت تعاني من ضیق تنفسي حاد.<br />&bull; إذا كنت تعاني من مرض كبدي.<br />&bull; إذا كنت تعاني من مرض كلوي معتدل أو حاد.<br />&bull; إذا كنت تشرب الكحولیات بإفراط (إما یومیا أو بكمیات كبیرة من حین لآخر).<br />&bull; إذا كنت مصاباً بالحماض السكري الكیتوني (أحد المضاعفات الحادة للسكري الخارج عن السیطرة). وتشمل الأعراض العطش<br />المفرط وكثرة التبول وفقدان الشھیة والغثیان أو القيء وفقدان الوزن السریع.<br />&bull; إذا كنت مصاباً بحمى حادة أو جفاف حاد (فقدت كمیة كبیرة من الماء الموجود بجسمك).<br />المحاذیر والاحتیاطات:<br />استشر طبیبك أو الصیدلي قبل تناول زایتیرو بلاس:<br />&bull;<br />&bull;<br />إذا كنت مصاباً بمرض السكري من النوع الأول(لا ینتج جسدك الأنسولین) .<br />إذا كنت تتناول زایتیرو بلاس مع الأنسولین أو الثیازولیدینیدیون. قد یرغب طبیبك في تخفیض جرعتك من الأنسولین أو<br />الثیازولیدینیدیون عندما تتناول كلاھما مع زایتیرو بلاس ، وذلك لتجنب الانخفاض المفرط في مستوي السكر بالدم )نوبة<br />ھبوط السكر بالدم.(<br />إذا كنت تتناول أي دواء آخر للسكري یحتوي على: السالفونیل یوریا&quot;، فعلیك ألا تبدأ بتناول زایتیرو بلاس.<br />إذا كنت ستجري عملیة جراحیة تحت التخدیر العام أو الشوكي أو الفوق جافي. قد ینصحك الطبیب بإیقاف تناول ھذا الدواء<br />لبعض الوقت قبل وبعد العملیة.<br />إذا كنت قد أصبت برد فعل تحسسي )تفاعل آرجي( لأي من العقاقیر الأخرى التي تساعد في السیطرة على مستوى السكر<br />بدمك. وقد تشمل الأعراض: الحكة العامة والإحساس بالحرارة وخصوصاً في فروة الرأس والفم والحلق وراحتي الكفین<br />وأخمصي القدمین (متلازمة ستیفن جونسون).<br />&bull; إذا كنت مصاباً بمرضٍ في البنكریاس أو أصبت بھ من قبل.</p><p>أثناء العلاج بزایتیرو بلاس، سیفحص طبیبك وظائف كلیتیك مرة واحدة على الأقل سنوی اً، وبمعدل أكثر تكراراً إذا كنت كبیراً في السن<br />أو إذا كانت وظائف كلیتیك غیر مستقرة أو معرضة للتدھور.<br />الأطفال والمراھقین:<br />لا یُوصى بزایتیرو بلاس للأطفال والمراھقین الأصغر سناً من ۱۸ عام بسبب انعدام البیانات في ھؤلاء المرضى.<br />العقاقیر الأخرى وزایتیرو بلاس:<br />أخبر طبیبك أو الصیدلي إذا كنت تتعاطى أو تناولت مؤخر اً أو قد تتناول أیة عقاقیر<br />أخرى.<br />أخبر طبیبك إذا كنت تتناول أي من الأدویة التالیة بشكل خاص:<br />&bull; الھیدروكورتیزون والبریدنیزولون (الكورتیكوسترویدات) المستخدمة لعلاج الأمراض التي تشمل الالتھاب مثل الربو والتھاب<br />المفاصل.<br />&bull; السیمیتدین، المستخدم لعلاج مشاكل المعدة.<br />&bull; موسعات الشعب الھوائیة (محفزات بیتا- ۲) والتي تستخدم لعلاج الربو.<br />&bull; رامیبریل ولیزینوبریل وإنالابریل (مثبطات الإنزیم المحول للأنجیوتنسین) المستخدم لعلاج ارتفاع ضغط الدم.<br />&bull; أقراص الماء (مدرات البول) التي تزید التبول.<br />&bull; عوامل التباین المعالجة بالیود التي تستخدم في التصویر بالأشعة السینیة.<br />&bull; الأدویة التي تحتوي على الكحول.</p><p>زایتیرو بلاس مع الكحول:<br />لا تتناول ھذا الدواء مع كمیات مفرطة من الكحول، فقد یعرضك ذلك بشكل أكبر للإصابة بالحماض اللاكتیكي، وھو من المضاعفات<br />الخطیرة التي یجب علاجھا بالمستشفى (أنظر الفقرة ٤ &quot;الأعراض الجانبیة المحتملة&quot;)<br />الحمل والرضاعة:<br />إذا كنتِ حاملا أو ترضعین أو تعتقدین أنھ من الممكن أن تكوني حاملا أو تخططین للحمل، فاطلبي المشورة من طبیبك أو الصیدلي<br />قبل تناول ھذا الدواء. یجب عدم تناول زایتیرو بلاس أثناء الحمل.<br />لا یُوصى باستعمال زایتیرو بلاس أثناء الرضاعة الطبیعیة لأن المیتفورمین یعبر إلى لبن الثدي.<br />القیادة واستخدام الآلات<br />لا یُعرف عن زایتیرو بلاس أنھ یؤثر على قدرتك على القیادة واستخدام الآلات. تناول زایتیرو بلاس في نفس الوقت مع عقار یسمى<br />بیوجلیتازون أو الأنسولین یمكن أن یسبب انخفاض حاد في معدل السكر بالدم (نوبة انخفاض السكر بالدم)، ما قد یؤثر على قدرتك على<br />القیادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;<br />&bull;<br />&bull;<br />&bull;<br />.<br />تناول زایتیرو بلاس فقاً لتعلیمات طبیبك بالضبط.<br />تناول زایتیرو بلاس مرتین یومیاً<br />تناول زایتیرو بلاس مع الطعام لتقلل من فرص إصابتك باضطراب المعدة.<br />لا تكسر أو تقطع أقراص زایتیرو بلاس قبل ابتلاعھا.<br />قد یحتاج طبیبك لتغییر جرعتك من زایتیرو بلاس للتحكم في مستوى السكر بدمك. لا تغیر جرعتك ما لم یأمرك طبیبك بذلك.<br />&bull; إذا فوَّ ت جرعة، فتناولھا بمجرد التذكر. أما إذا لم تتذكر حتى میعاد الجرعة التالیة، فتجاوز عن الجرعة الفائتة، وتناول الجرعة<br />&bull;<br />التالیة في موعدھا المعتاد. لا تتناول جرعتین من زایتیرو بلاس في نفس الوقت.<br />إذا تناولت الكثیر من زایتیرو بلاس ، فاتصل بطبیبك أو أذھب لغرفة الطوارئ بأقرب مستشفى على الفور.<br />&bull;<br />إذا كان جسدك یعاني من الإجھاد نتیجة الحمى أو العدوى أو حادثة أو جراحة، فإن جرعة دواء السكري خاصتك قد تحتاج لتعدیل.<br />اتصل بطبیبك فوراً.<br />&bull;<br />حافظ على حمیتك الغذائیة وبرنامج تمارینك الریاضیة وافحص مستوى السكر في الدم حسب تعلیمات الطبیب.<br />&bull;<br />&bull;<br />قد یقوم طبیبك المعالج ببعض الفحوصات المعینة قبل أن تبدأ في استخدام ڤیبدومت وخلال العلاج حسب الحاجة. وقد یطلب طبیبك أن<br />توقف استخدام ڤیبدومت بناءً على نتائج فحوصات الدم التي أُجریت لك وفقاً لمدى جودة أداء كلیتیك لوظیفتیھما.<br />. A1C سیتابع طبیبك مرض السكري من خلال فحوصات الدم الدوریة والتي تتضمن مستوي السكر في الدم واختبار الھیموجلوبین<br />إذا تناولت جرعة زائدة عن المفترض من زایتیرو بلاس:<br />إذا تناولت أقراص أكثر من الجرعة المفترضة، أو إذا تناول شخص آخر أو طفل عقارك، فاتصل أو أذھب لأقرب مركز طوارئ فوراً.<br />وخذ ھذه النشرة أو بعض الأقراص معك حتى یعرف طبیبك ماذا تناولت بالضبط.</p><p>&nbsp;</p><p>إذا نسیت تناول زایتیرو بلاس:<br />إذا فوَّ ت جرعة، فتناولھا بمجرد التذكر. لا تتناول جرعة مضاعفة لتعویض الجرعة التي نسیتھا.<br />إذا توقفت عن تناول زایتیرو بلاس:<br />لا تتوقف عن تناول زایتیرو بلاس بدون استشارة طبیبك أولًا . فقد یرتفع مستوى السكر بدمك عندما تتوقف عن تناول زایتیرو بلاس.<br />إذا كانت لدیك مزید من الأسئلة عن استخدام ھذا الدواء فاسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع العقاقیر، فإن ھذا الدواء قد یتسبب في حدوث آثار جانبیة، رغم أن ذلك لا یحدث في كل الحالات.<br />توقف عن تناول زایتیرو بلاس واتصل بالطبیب فوراً إذا لاحظت أیا من الآثار الجانبیة الخطیرة التالیة:<br />( شدیدة الندرة )قد تصیب حتى ۱ من بین كل ۱۰٫۰۰۰ شخص:<br />&bull; الحماض اللاكتیكي (تراكم حمض اللاكتیك في الدم). الحماض اللاكتیكي ھو حالة طبیة طارئة ویجب علاجھا بالمستشفى.<br />ویمكنھا أن تؤثر بشكل خاص على المرضى المصابین بقصور الكلى. وتشمل الأعراض بعض أو كل ما یلي: الإحساس بالبرد<br />أو الضیق أو الغثیان الحاد مع أو بدون القيء وفقدان الوزن غیر المبرر وتسارع معدل التنفس.<br />غیر معروف (لا یمكن تقییم التكرار من البیانات المتاحة):<br />&bull; رد فعل تحسسي (التفاعل الآرجي). قد تشمل الأعراض: الطفح أو الشرى أو التورم أو مشاكل التنفس أو تورم الشفاه أو الوجھ<br />أو الحلق أو اللسان والشعور بالإغماء.<br />&bull; التفاعل الآرجي الحاد: آفات الجلد أو البقع على جلدك والتي یمكن أن تتطور لتصیر قرحة محاطة بحلقات باھتة أو حمراء،<br />وتكون البثور المتقرحة و/ أو تقشر الجلد وقد یصاحب ذلك أعراض مثل الحكة والحمى وشعور عام بالإعیاء وألم المفاصل<br />ومشاكل بالإبصار وشعور بالحرقان و الألم أو الحكة بالعین وقرح الفم (متلازمة ستیفن جونز والحمامى العدیدة الأشكال).<br />&bull; الألم الحاد والمستمر في البطن (منطقة المعدة) والذي قد ینتشر إلى ظھرك، بالإضافة للغثیان والقيء وھو ما قد یكون علامة<br />على التھاب البنكریاس.<br />كما یجب أن تناقش طبیبك إذا شعرت بالآثار الجانبیة التالیة:<br />شائعة جد ا (ًقد تصیب أكثر من ۱ من بین كل ۱۰ أشخاص):<br />&bull; مغص المعدة.<br />&bull; الإسھال.<br />&bull; فقدان الشھیة.<br />&bull; الغثیان.<br />&bull; الإعیاء.</p><p>شائعة (قد تصیب حتى ۱ من بین كل ۱۰ أشخاص) :<br />&bull; أعراض انخفاض مستوى السكر بالدم (نوبة ھبوط سكر الدم) قد تحدث عندما یتم تناول زایتیرو بلاس مع الأنسولین أو<br />السالفونایل یوریا (مثل جلیبیزاید وتولبیوتاماید وجلیبینكلاماید). وقد تشمل الأعراض: الرعشة أو التعرق أو الاضطراب أو<br />الزغللة أو خدر الشفاه أو الشحوب أو التغیرات المزاجیة أو الشعور بالارتباك. وقد یھبط مستوى السكر بدمك تحت المستوى<br />الطبیعي، لكنھ یرتفع مجدداً بتناول السكر. ویُوصى بأن تحمل معك بضع مكعبات من السكر أو الحلوى أو البسكویت أو عصیر<br />الفواكھ الغني بالسكر.<br />أعراض البرد مثل: احتقان الحلق أو رشح وانسداد الأنف أو الشعور بالإرھاق أو الحمى أو الرعشة أو السعال الجاف<br />الطفح<br />حكة الجلد مع أو بدون شرى<br />الصداع<br />عسر الھضم والحموضة<br />القيء و/أو الإسھال.<br />شدید الندرة:<br />&bull; انخفاض مستوى فیتامین ب ۱۲ أو الأنیمیا، وتشمل الأعراض: الإرھاق والخمول والشعور بالإغماء والإصابة بعسر التنفس.<br />&bull; مشاكل الكبد (الالتھاب الكبدي).</p><p>غیر معروفة:<br />مشاكل الكبد مثل الغثیان، القيء، ألم المعدة، الإعیاء غیر المعتاد أو المفسر، فقدان الشھیة، البول الداكن أو اصفرار دلجلا أو بیاض<br />العینین.<br />الإبلاغ عن الآثار الجانبیة<br />إذا حدثت لك أیة آثار جانبیة، تحدث إلى طبیبك أو الصیدلي. بما في ذلك أیة آثار جانبیة غیر مدرجة بھذه النشرة. كما بإمكانك الإبلاغ<br />عن الآثار الجانبیة عن طریق المركز الوطني للتیقظ و السلامة الدوائیة المشار إلیھ في أسفل ھذه النشرة یمكنك المساعدة في توفیر<br />المزید من المعلومات عن سلامة ھذا العقار بالإبلاغ عن الآثار الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُخزن في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />احتفظ بعبوة ڤیبدومت مغلقة بإحكام..<br />احتفظ بھذا الدواء بعیداً عن متناول ونظر الأطفال.<br />یشیر تاریخ انتھاء الصلاحیة إلى آخر .(EXP) لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المدون على العلبة و الشریط بعد كلمة<br />یومٍ في الشھر المذكور.<br />لا تلقي أي أدویة في مصارف المیاه أو القمامة المنزلیة. اسأل الصیدلي عن طریقة التخلص من أي دواء لا تستخدمھ. ستساعد ھذه<br />التدابیر في الحفاظ على البیئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر أقراص زایتیرو بلاس في التركیزات والعبوات<br />التالیة :<br />زایتیرو بلاس ۱۲٫٥ ملجم + ٥۰۰ ملجم: أقراص مغلفة صفراء باھتة، مستطیلة ومحدبة الجانبین منقوش على جانب واحد علامة<br />. &ldquo;322M&rsquo;&rsquo; 500 &ldquo; و على الجانب الآخر علامة &rdquo;/12.5<br />زایتیرو بلاس ۱۲٫٥ ملجم + ۱۰۰۰ ملجم: أقراص مغلفة صفراء باھتة، مستطیلة ومحدبة الجانبین منقوش على جانب واحد علامة<br />. &ldquo;322M&rsquo;&rsquo; 1000 &ldquo; و على الجانب الآخر علامة &rdquo;/12.5<br />یتوفر زایتیرو بلاس في عبوات تحتوي على ٥٦ قرصاً (العبوة تحتوي على ۸ شرائط یحتوي كل منھا على ۷ أقراص).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ماذا یحتوي زایتیرو بلاس<br />-المواد الفعالة ھي ألوجلیبتین و میتفورمین ھیدروكلورید.<br />كل قرص مغلف ۱۲٫٥ ملجم / ٥۰۰ ملجم یحتوي على بنزوات الألوجلیبتین بما یعادل ۱۲٫٥ ملجم من الألوجلیبتین و ٥۰۰ ملجم من<br />المیتفورمین ھیدروكلورید.<br />كل قرص مغلف ۱۲٫٥ ملجم / ۱۰۰۰ ملجم یحتوي على بنزوات الألوجلیبتین بما یعادل ۱۲٫٥ ملجم من الألوجلیبتین و ۱۰۰۰ ملجم من<br />المیتفورمین ھیدروكلورید.<br />المكونات الأخرى ھي: مانیتول، ومایكروكریستالین سیلیلوز، وبوفیدون، وكروسبوفیدون، وسترات الماغنیسیوم. الأقراص مغلفة بطبقة<br />ھیبرومیلوز ۲۹۱۰ وتلك، ودایوكسید التیتانیوم، وأكسید الحدید الأصفر (فریك أوكسید) .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب رخصة التسویق، موقع التعبئة والتغلیف الثانوي وموقع الإفراج النھائي:<br />Batterjee pharmaceutical factory<br />Industrial Area-phase-IV,<br />Jeddah-21443, Kingdom of Saudi<br />:</p><p>المصنع:<br />Takeda Pharmaceutical Company Limited<br />17-85 Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan</p><p>موقع التعبئة والتغلیف الأولي:<br />Packaging Coordinators, LLC<br />2200 Lake Shore Drive,<br />Woodstock, IL 60098, USA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ینایر 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zytero Plus 12.5 mg/500 mg film-coated tablets Zytero Plus 12.5 mg/1000 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - The active substances are alogliptin and metformin hydrochloride.
Each 12.5 mg/500 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 500 mg metformin hydrochloride.
Each 12.5 mg/1000 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin and 1000 mg metformin hydrochloride.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
12.5mg+500mg tablet: Pale yellow, oblong , biconvex, film-coated tablet with “12.5/500” debossed on one side and “322M” debossed on the other side.
12.5mg+1000mg tablet: Pale yellow, oblong ,biconvex, film-coated tablet with “12.5/1000” debossed on one side and “322M” debossed on the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1.1 Monotherapy and Combination Therapy<br />ZYTERO PLUS is indicated as an adjunct to diet and exercise to improve glycemic control<br />in adults ( &ge; 18 years) with type 2 diabetes mellitus in multiple clinical settings when treatment with both alogliptin and metformin is appropriate.<br />4.1.2 Limitation of Use<br />ZYTERO PLUS should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.2.1 Posology<br />For the different dose regimens Zytero Plus is available in strengths of 12.5 mg/500 mg and<br />12.5 mg/1000 mg film-coated tablets<br />4.2.2 Recommendations for All Patients<br />&bull; Healthcare providers should individualize the starting dose of ZYTERO PLUS based on the patient&rsquo;s current regimen.<br />&bull; ZYTERO PLUS should be taken twice daily with food with gradual dose escalation to reduce the gastrointestinal (GI) side effects due to metformin. ZYTERO PLUS tablets<br />3<br />must not be split before swallowing.<br />&bull; Dosing may be adjusted based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 25 mg alogliptin and 2000 mg metformin HCl.</p><p>4.2.3 Special populations<br />Elderly (&ge; 65 years old)<br />No dose adjustment is necessary based on age. However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population<br />Renal impairment<br />For patients with mild renal impairment (creatinine clearance &ge; 60 mL/min), no dose adjustment of Zytero Plus is necessary (see section 5.2).<br />As Zytero Plus contains metformin, it must not be used in patients with moderate or severe renal impairment or end-stage renal disease requiring dialysis (creatinine clearance &lt; 60 mL/min) (see sections 4.3, 4.4 and 5.2).<br />Appropriate assessment of renal function is recommended prior to initiation of Zytero Plus and at regular intervals thereafter (see section 4.4).<br />Hepatic impairment<br />Zytero Plus should not be used in patients with hepatic impairment (see sections 4.3 and 5.2).<br />Paediatric population<br />The safety and efficacy of Zytero Plus in children and adolescents &lt; 18 years old have not been established. No data are available.</p><p>Method of administration<br />Oral use.<br />Zytero Plus should be taken twice daily because of the pharmacokinetics of its metformin component. It should also be taken with meals to reduce the gastrointestinal adverse reactions associated with metformin. The tablets should be swallowed whole with water.<br />If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken at the same time. In that case, the missed dose should be skipped.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8)
 Diabetic ketoacidosis, diabetic pre-coma
 Moderate and severe renal impairment and end-stage renal disease (creatinine clearance
< 60 mL/min; see section 4.4)
 Acute conditions with the potential to alter renal function such as:
o dehydration
o severe infection
o shock
 Acute or chronic disease which may cause tissue hypoxia (see section 4.4) such as:
o cardiac or respiratory failure
o recent myocardial infarction
o shock
 Hepatic impairment (see section 4.4)
 Acute alcohol intoxication, alcoholism (see sections 4.4 and 4.5)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Zytero Plus should not be used in patients with type 1 diabetes mellitus. Zytero Plus is not a substitute for insulin in insulin-requiring patients.<br />Lactic acidosis<br />Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation. Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure. The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any conditions associated with hypoxia.<br />Diagnosis<br />A diagnosis of lactic acidosis must be considered in the event of non-specific symptoms such as muscle cramps and/or abdominal pain and/or severe asthenia. Lactic acidosis is further characterised by acidotic dyspnoea and hypothermia followed by coma. Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/L, an increased anion gap and lactate/pyruvate ratio. If metabolic acidosis is suspected, treatment with Zytero Plus should be discontinued and the patient hospitalised immediately (see section 4.9).<br />Renal function</p><p>Alogliptin and metformin are substantially excreted by the kidney. The risk of metformin-related lactic acidosis increases with the degree of renal impairment, therefore, serum creatinine concentrations should be determined (and corresponding estimated glomerular filtration rate or creatinine clearance estimated) before initiating treatment and regularly thereafter:<br /> at least once a year in patients with normal renal function<br /> at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly patients<br />Decreased renal function in elderly patients is frequent and asymptomatic. Special caution should be exercised in situations where renal function may become impaired, for example when initiating antihypertensive or diuretic therapy or when starting treatment with a nonsteroidal anti-inflammatory drug (NSAID).<br />Zytero Plus is not recommended for use in patients with moderate and severe renal impairment and end-stage renal disease (creatinine clearance &lt; 60 mL/min)(see section 4.3).<br />Hepatic impairment<br />Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt;9) and is, therefore, not recommended for use in such patients (see sections 4.2, 4.3 and 5.2).<br />Surgery</p><p>As Zytero Plus contains metformin, treatment should be discontinued 48 hours before elective surgery with general, spinal or epidural anaesthesia. Treatment should not usually be resumed earlier than<br />48 hours afterwards, and only after renal function has been re-evaluated and found to be normal.<br />5<br />Administration of iodinated contrast agents<br />The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure which has been associated with lactic acidosis in patients receiving metformin. Therefore, Zytero Plus should be discontinued prior to, or at the time of, the test and not reinstituted until<br />48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).</p><p>Use with other antihyperglycaemic medicinal products and hypoglycaemia<br />Insulin is known to cause hypoglycaemia. Therefore, a lower dose of insulin may be considered to reduce the risk of hypoglycaemia when this medicinal product is used in combination with Zytero Plus (see section 4.2).<br />Due to the increased risk of hypoglycaemia in combination with pioglitazone, a lower dose of pioglitazone may be considered to reduce the risk of hypoglycaemia when this drug is used in combination with Zytero Plus (see section 4.2).<br />Combinations not studied<br />Zytero Plus should not be used in combination with a sulphonylurea, as the safety and efficacy of this combination have not been fully established.<br />Change in clinical status of patients with previously controlled type 2 diabetes mellitus<br />As Zytero Plus contains metformin, any patient with type 2 diabetes mellitus previously well controlled on Zytero Plus who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate and metformin levels. If acidosis of either form occurs, Zytero Plus must be stopped immediately and other appropriate corrective measures initiated.<br />Hypersensitivity reactions</p><p>Hypersensitivity reactions, including anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting. In clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence.<br />Acute pancreatitis<br />Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. In a pooled analysis of the data from 13 studies, the overall rates of pancreatitis reports in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo were 2, 1, 1 or 0 events per<br />1,000 patient years, respectively. In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively. There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, which may radiate to the back. If pancreatitis is suspected, Zytero Plus should be discontinued; if acute pancreatitis is confirmed, Zytero Plus should not be restarted. Caution should be exercised in patients with a history of pancreatitis.<br />Hepatic effects</p><p>Postmarketing reports of hepatic dysfunction including hepatic failure have been received. A causal relationship has not been established. Patients should be observed closely for possible liver<br /><br />abnormalities. Obtain liver function tests promptly in patients with symptoms suggestive of liver injury. If an abnormality is found and an alternative etiology is not established, consider discontinuation of alogliptin treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Co-administration of 100 mg alogliptin once daily and 1,000 mg metformin hydrochloride twice daily for 6 days in healthy subjects had no clinically relevant effects on the pharmacokinetics of alogliptin or metformin.<br />Specific pharmacokinetic drug interaction studies have not been performed with Zytero Plus . The following section outlines the interactions observed with the individual components of Zytero Plus (alogliptin/metformin) as reported in their respective Summary of Product Characteristics.<br />Effects of other medicinal products on alogliptin<br />Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2). Interactions with CYP inhibitors are thus not expected and have not been shown.<br />Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin.<br />Effects of alogliptin on other medicinal products<br />In vitro studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). Interaction with substrates of CYP 450 isoforms are thus not expected and have not been shown. In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with drug disposition&nbsp;in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2). Furthermore, clinical data do not suggest interaction with p-glycoprotein inhibitors or substrates.<br />In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine,<br />metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.<br />In healthy subjects, alogliptin had no effect on prothrombin time or International Normalised Ratio (INR) when administered concomitantly with warfarin.<br />Combination of alogliptin with other anti-diabetic medicinal products<br />Results from studies with metformin, pioglitazone (thiazolidinedione), voglibose (alpha-glucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions.</p><p>Interactions with metformin<br />Combinations not recommended<br />Alcohol<br />There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic impairment) due to the metformin component (see section 4.4). Consumption of alcohol and medicinal products containing alcohol should be avoided.<br />Cationic medicinal products<br />Cationic substances that are eliminated by renal tubular secretion (e.g. cimetidine) may interact with metformin by competing for common renal tubular transport systems. A study conducted in seven normal healthy volunteers showed that cimetidine (400 mg twice daily) increased metformin systemic exposure (area under the curve, AUC) by 50% and Cmax by 81%. Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic medicinal products that are eliminated by renal tubular secretion are co-administered.<br />Iodinated contrast agents<br />The intravascular administration of iodinated contrast agents may lead to renal failure resulting in metformin accumulation and a risk of lactic acidosis. Therefore, Zytero Plus should be discontinued prior to, or at the time of, the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.4).<br />Combination requiring precautions for use</p><p>Medicinal products with intrinsic hyperglycaemic activity<br />Glucocorticoids (given by systemic and local routes), beta-2-agonists and diuretics (see also<br />section 4.4) have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. If necessary, the dose of Zytero Plus should be adjusted during therapy with the other medicinal product and upon its discontinuation.<br />ACE inhibitors<br />Angiotensin-converting-enzyme (ACE) inhibitors may decrease blood glucose levels. If necessary, the dose of Zytero Plus should be adjusted during therapy with the other medicinal product and upon its discontinuation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy Category B<br />There are no data from the use of Zytero Plus in pregnant women. Studies in pregnant rats with alogliptin plus metformin as combination treatment have shown reproductive toxicity at approximately 5-20 times (for metformin and alogliptin respectively) the human exposure at the recommended dose.<br />Zytero Plus should not be used during pregnancy.<br />Risk related to alogliptin<br />There are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>Risk related to metformin<br />A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses (see section 5.3).<br />Breast-feeding<br />No studies in lactating animals have been conducted with the combined active substances of Zytero Plus . In studies performed with the individual active substances, both alogliptin and metformin were excreted in the milk of lactating rats. It is unknown whether alogliptin is excreted in human milk.<br />Metformin is excreted in human milk in small amounts. A risk to the suckling child cannot be excluded.<br />A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zytero Plus therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.<br />Fertility<br />The effect of Zytero Plus on fertility in humans has not been studied. No adverse effects on fertility were observed in animal studies conducted with alogliptin or with metformin (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zytero Plus has no or negligible influence on the ability to drive and use machines. However, patients should be alerted to the risk of hypoglycaemia especially when used in combination with insulin or pioglitazone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Clinical studies conducted to support the efficacy and safety of Zytero Plus involved the co-administration of alogliptin and metformin as separate tablets. However, the results of<br />bioequivalence studies have demonstrated that Zytero Plus film-coated tablets are bioequivalent to the corresponding doses of alogliptin and metformin co-administered as separate tablets.<br />The information provided is based on a total of 7,150 patients with type 2 diabetes mellitus, including 4,201 patients treated with alogliptin and metformin, who participated in 7 phase 3 double-blind, placebo- or active-controlled clinical studies. These studies evaluated the effects of co-administered alogliptin and metformin on glycaemic control and their safety as initial combination therapy, as dual therapy in patients initially treated with metformin alone, and as add-on therapy to a thiazolidinedione or insulin.<br />The safety profile of co-administered alogliptin and metformin was consistent with that of the individual components as demonstrated in clinical trials for alogliptin and from the comprehensive data available for metformin. As such, the following section outlines the adverse reactions of the individual components of Zytero Plus (alogliptin/metformin) as reported in their respective Summary of Product Characteristics.</p><p>Alogliptin<br />The information provided is based on a total of 9,405 patients with type 2 diabetes mellitus, including 3,750 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, who participated in one phase 2 or 12 phase 3 double-blind, placebo- or active-controlled clinical studies. In addition, a cardiovascular outcomes study with 5,380 patients with type 2 diabetes mellitus and a recent acute coronary syndrome event was conducted with 2,701 randomised to alogliptin and 2,679 randomised to placebo. These studies evaluated the effects of alogliptin on glycaemic control and its safety as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).<br />In a pooled analysis of the data from 13 studies, the overall incidences of adverse events, serious adverse events and adverse events resulting in discontinuation of therapy were comparable in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active-control or placebo. The most common adverse reaction in patients treated with 25 mg alogliptin was headache.<br />The safety of alogliptin between the elderly (&ge; 65 years old) and non-elderly (&lt; 65 years old) was similar.<br />Tabulated list of adverse reactions<br />The adverse reactions are listed by system organ class and frequency. Frequencies are defined as very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to&nbsp;&lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from available data).</p><p>Alogliptin<br />In the pooled pivotal phase 3 controlled clinical trials of alogliptin as monotherapy and as add-on combination therapy, involving 5,659 patients, the observed adverse reactions are listed below (Table 1).<br />Table 1: Adverse reactions observed in pooled pivotal phase 3 controlled clinical studies<br />System Organ Class<br />Adverse reaction&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Frequency of adverse reactions</p><p>Infections and infestations&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Common<br />Upper respiratory tract infections Nasopharyngitis<br /><br />Nervous system disorders<br />Headache&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Common<br /><br />Gastrointestinal disorders&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Common<br />Abdominal pain Gastroesophageal reflux disease<br /><br />Skin and subcutaneous tissue disorders&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Common<br />Pruritus Rash<br />&nbsp;</p><p>Alogliptin/metformin<br />In the pooled pivotal phase 3 controlled clinical trials of alogliptin as add-on combination therapy to metformin, involving 7,151 patients, the observed adverse reactions are listed below (Table 2).<br />Table 2: Adverse reactions observed in pooled pivotal phase 3 controlled clinical studies<br />System Organ Class<br />Adverse reaction<br />Frequency of adverse reactions<br />Infections and infestations<br />Upper respiratory tract infections Nasopharyngitis<br />Common Common</p><p><br />Nervous system disorders<br />Headache<br />Common</p><p><br />Gastrointestinal disorders Gastroenteritis Abdominal pain Diarrhoea Vomiting<br />Gastritis<br />Gastroesophageal reflux disease<br />Common Common Common Common Common Common</p><p><br />Skin and subcutaneous tissue disorders<br />Pruritus Rash<br />Common</p><p>Alogliptin<br />Post-marketing experience<br />Table 3 shows additional adverse reactions which have been spontaneously reported post-marketing.<br />Table 3: Spontaneously reported alogliptin post-marketing adverse reactions<br />System Organ Class<br />Adverse reaction<br />Frequency of adverse reactions<br />Immune system disorders<br />Hypersensitivity<br />Not known</p><p><br />Gastrointestinal disorders<br />Acute pancreatitis<br />Not known</p><p><br />Hepatobiliary disorders<br />Hepatic dysfunction including hepatic failure<br />Not known</p><p><br />Skin and subcutaneous tissue disorders Exfoliative skin conditions including Stevens-Johnson syndrome Erythema multiforme<br />Angioedema Urticaria<br />Not known Not known Not known Not known</p><p>Metformin<br />Clinical trial data and post-marketing experience<br />Table 4 shows additional adverse reactions which have been reported from clinical trials and post- marketing.<br />Table 4: Frequency of metformin adverse reactions identified from clinical trial data<br />and post-marketing experience<br />System Organ Class<br />Adverse reaction<br />Frequency of adverse reactions<br />Metabolism and nutrition disorders<br />Lactic acidosis<br />Vitamin B12 deficiency<br />Very rare Very rare</p><p><br />Nervous system disorders<br />Metallic taste<br />Common</p><p><br />Gastrointestinal disorders Abdominal pain Diarrhoea<br />Loss of appetite Nausea Vomiting<br />Very common Very common Very common Very common Very common</p><p><br />Hepatobiliary disorders<br />Hepatitis<br />Liver function test abnormalities<br />Very rare Very rare</p><p><br />Skin and subcutaneous tissue disorders<br />Erythema Pruritus Urticaria<br />Very rare Very rare Very rare</p><p><br />Description of selected adverse reactions<br />Lactic acidosis:&nbsp;0.03 cases/1000 patient-years (see section 4.4).</p><p>Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption and appears generally to be without clinical significance. However, it may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia).<br />Gastrointestinal symptoms occur most frequently during initiation of therapy and resolve spontaneously in most cases. These may be prevented by taking metformin in 2 daily doses during or after meals.<br />Isolated cases of hepatitis or liver function test abnormalities resolving on discontinuation of metformin have been reported.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance and Drug Safety Centre (NPC) listed below:<br />To report any side effect(s):<br /> Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available with regard to overdose of Zytero Plus . Alogliptin<br />The highest doses of alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes mellitus (equivalent to 32 times and 16 times the recommended total daily dose of 25 mg alogliptin, respectively).<br />Metformin<br />A large overdose of metformin or concomitant risks may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital.</p><p>Management<br />In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient&rsquo;s clinical status.<br />Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session). Therefore, haemodialysis is of little clinical benefit in removing alogliptin in overdose. It is not known if alogliptin is removed by peritoneal dialysis.<br />The most effective method of removing lactate and metformin is haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes; combinations of oral blood glucose lowering drugs.<br />ATC code: A10BD13.<br />Mechanism of action and pharmacodynamic effects<br />Zytero Plus combines two antihyperglycaemic medications with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and metformin, a member of the biguanide class.<br />Alogliptin<br />Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt;10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. DPP-4 is the principal enzyme involved in the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and GIP<br />(glucose-dependent insulinotropic polypeptide), which are released by the intestine and levels are increased in response to a meal. GLP-1 and GIP increases insulin biosynthesis and secretion from pancreatic beta cells, while GLP-1 also inhibits glucagon secretion and hepatic glucose production. Alogliptin therefore improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.<br />Metformin</p><p>Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and, therefore, does not produce hypoglycaemia.<br />Metformin may act via 3 mechanisms:<br />- by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis.<br />- in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation.<br />- by delaying intestinal glucose absorption.<br />Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase. It also increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4).</p><p>In humans, independently of its action on glycaemia, metformin has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies; metformin reduces total cholesterol, LDL cholesterol and triglyceride levels.<br />Clinical efficacy<br />Clinical studies conducted to support the efficacy of Zytero Plus involved the co-administration of alogliptin and metformin as separate tablets. However, the results of bioequivalence studies have demonstrated that Zytero Plus film-coated tablets are bioequivalent to the corresponding doses of alogliptin and metformin co-administered as separate tablets.<br />The co-administration of alogliptin and metformin has been studied as dual therapy in patients initially treated with metformin alone, and as add-on therapy to a thiazolidinedione or insulin.<br />Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing. Inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing.<br />When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL.<br />Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p&lt;0.05). In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant&nbsp;(p&lt;0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo.<br />A total of 7,151 patients with type 2 diabetes mellitus, including 4,202 patients treated with alogliptin and metformin, participated in 7 phase 3 double-blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of co-administered alogliptin and metformin on glycaemic control and their safety. In these studies, 696 alogliptin/metformin-treated patients were &ge; 65 years old.<br />Overall, treatment with the recommended total daily dose of 25 mg alogliptin in combination with metformin improved glycaemic control. This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint. Reductions in HbA1c were similar across different subgroups including renal impairment, age, gender and body mass index, while differences between races (e.g.<br />White and non-White) were small. Clinically meaningful reductions in HbA1c compared to control were also observed regardless of baseline background treatment. Higher baseline HbA1c was associated with a greater reduction in HbA1c. Generally, the effects of alogliptin on body weight and lipids were neutral.<br />Alogliptin as add-on therapy to metformin<br />The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean<br />dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 5). Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (18.3%) at Week 26 (p&lt;0.001).</p><p>The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean<br />dose = 1,835 mg) resulted in improvements from baseline in HbA1c at Week 52 and Week 104. At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 6) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean<br />dose = 1,824 mg, -0.73%). At Week 104, the HbA1c reduction by 25 mg alogliptin plus metformin (- 0.72%, Table 6) was greater than that produced by glipizide plus metformin (-0.59%). Mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin and metformin was significantly greater than that for glipizide and metformin (p&lt;0.001). By Week 104, mean change from baseline in fasting plasma glucose for 25 mg alogliptin and metformin was -3.2 mg/dL compared with 5.4 mg/dL for glipizide and metformin. More patients receiving 25 mg alogliptin and metformin (48.5%) achieved target HbA1c levels of &le; 7.0% compared to those receiving glipizide and metformin (42.8%) (p=0.004).<br />Co-administration of 12.5 mg alogliptin and 1,000 mg metformin hydrochloride twice daily resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to either 12.5 mg alogliptin twice daily alone or 1,000 mg metformin hydrochloride twice daily alone. Significantly more patients receiving 12.5 mg alogliptin and 1.000 mg metformin hydrochloride twice daily (59.5%) achieved target HbA1c levels of &lt; 7.0% compared to those receiving either 12.5 mg alogliptin twice daily alone (20.2%, p&lt;0.001) or 1,000 mg metformin hydrochloride twice daily alone (34.3%, p&lt;0.001) at Week 26.<br />Alogliptin as add-on therapy to metformin with a thiazolidinedione<br />The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 5).</p><p>Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).<br />The addition of 25 mg alogliptin once daily to 30 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,847.6 mg,<br />Table 6). The significant reductions in HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p&lt;0.001 at all time points). In addition, mean change from baseline in FPG at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p&lt;0.001). Significantly more patients receiving<br />25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of<br /> 7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p&lt;0.001).<br />Alogliptin as add-on therapy to metformin with insulin<br />The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 5). Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin therapy. More patients receiving 25 mg alogliptin (7.8%)&nbsp;achieved target HbA1c levels of  7.0% compared to those receiving placebo (0.8%) at Week 26.</p><p>Elderly (&ge; 65 years old)<br />The efficacy and safety of the recommended doses of alogliptin and metformin in a subgroup of patients with type 2 diabetes mellitus and &ge; 65 years old were reviewed and found to be consistent with the profile obtained in patients &lt; 65 years old.<br />Clinical safety<br />Cardiovascular Safety<br />In a pooled analysis of the data from 13 studies, the overall incidences of cardiovascular death, non fatal myocardial infarction and non-fatal stroke were comparable in patients treated with 25 mg alogliptin, active control or placebo.<br />In addition, a prospective randomized cardiovascular outcomes safety study was conducted with 5,380 patients with high underlying cardiovascular risk to examine the effect of alogliptin compared with placebo (when added to standard of care) on major adverse cardiovascular events (MACE) including time to the first occurrence of any event in the composite of cardiovascular death, nonfatal&nbsp;myocardial infarction and nonfatal stroke in patients with a recent (15 to 90 days) acute coronary event. At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%.<br />The study demonstrated that alogliptin did not increase the risk of having a MACE compared to placebo [Hazard Ratio: 0.96; 1-sided 99% Confidence Interval: 0-1.16]. In the alogliptiThere were 703 patients who experienced an event within the secondary MACE composite endpoint (first event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina). In the alogliptin group, 12.7% (344 subjects) experienced an event within the secondary MACE composite endpoint, compared with 13.4% (359 subjects) in the placebo group [Hazard Ratio = 0.95; 1-sided 99% Confidence Interval: 0-1.14].<br />Hypoglycaemia<br />In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with 25 mg alogliptin than in patients treated with<br />12.5 mg alogliptin, active control or placebo (3.6%, 4.6%, 12.9% and 6.2%, respectively). The majority of these episodes were mild to moderate in intensity. The overall incidence of episodes of severe hypoglycaemia was comparable in patients treated with 25 mg alogliptin or 12.5 mg alogliptin, and lower than the incidence in patients treated with active control or placebo (0.1%, 0.1%, 0.4% and 0.4%, respectively). In the prospective randomized controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and patients receiving alogliptin (6.7%) in addition to standard of care.<br />In a clinical trial of alogliptin as mono-therapy, the incidence of hypoglycaemia was similar to that of placebo, and lower than placebo in another trial as add-on to a sulphonylurea.<br />Higher rates of hypoglycaemia were observed with triple therapy with a thiazolidinedione and metformin and in combination with insulin, as observed with other DPP-4 inhibitors.<br />Patients (&ge; 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients &lt; 65 years old. In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients &ge; 65 years old treated&nbsp;25 mg alogliptin (3.8%) to that in patients &lt; 65 years old (3.6%).<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies with Zytero Plus in all subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The results of bioequivalence studies in healthy subjects demonstrated that Zytero Plus film-coated tablets are bioequivalent to the corresponding doses of alogliptin and metformin co-administered as separate tablets.<br />Co-administration of 100 mg alogliptin once daily and 1,000 mg metformin hydrochloride twice daily for 6 days in healthy subjects had no clinically relevant effects on the pharmacokinetics of alogliptin or metformin.<br />Administration of Zytero Plus with food resulted in no change in total exposure (AUC) to alogliptin or metformin. However, mean peak plasma concentrations of alogliptin and metformin were decreased by 13% and 28% when Zytero Plus was administered with food, respectively. There was no change in the time to peak plasma concentration (Tmax) for alogliptin, but there was a delayed Tmax for metformin of 1.5 hours. These changes are not likely to be clinically significant (see below).<br />Zytero Plus should be taken twice daily because of the pharmacokinetics of its metformin component. It should also be taken with meals to reduce the gastrointestinal undesirable effects associated with metformin (see section 4.2).<br />The pharmacokinetics of Zytero Plus in children and adolescents &lt; 18 years old has not been established. No data are available (see section 4.2).<br />The following section outlines the pharmacokinetic properties of the individual components of Zytero Plus (alogliptin/metformin) as reported in their respective Summary of Product Characteristics.</p><p>Alogliptin<br />The pharmacokinetics of alogliptin has been shown to be similar in healthy subjects and in patients with type 2 diabetes mellitus.<br />Absorption<br />The absolute bioavailability of alogliptin is approximately 100%.<br />Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. Alogliptin may, therefore, be administered with or without food.<br />After administration of single oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax) after dosing.<br />No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus.<br />Total and peak exposure to alogliptin increased proportionately across single doses of 6.25 mg up to 100 mg alogliptin (covering the therapeutic dose range). The inter-subject coefficient of variation for alogliptin AUC was small (17%).<br />Distribution</p><p>Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the drug is well distributed into tissues.<br />Alogliptin is 20-30% bound to plasma proteins.</p><p>Biotransformation<br />Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged drug in the urine.<br />Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I (&lt; 1% of the parent compound), and N-acetylated alogliptin,<br />M-II (&lt; 6% of the parent compound). M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.<br />In vitro studies indicate that alogliptin does not induce CYP1A2, CYP2B6 and CYP2C9 and does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin. Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo.<br />In studies in vitro, alogliptin was not an inhibitor of the following renal transporters; OAT1, OAT3 and OCT2.<br />Alogliptin exists predominantly as the (R)-enantiomer (&gt; 99%) and undergoes little or no chiral conversion in vivo to the (S)-enantiomer. The (S)-enantiomer is not detectable at therapeutic doses.<br />Elimination<br />Alogliptin was eliminated with a mean terminal half-life (T1/2) of approximately 21 hours.</p><p>Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces.<br />The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx. 120 mL/min), suggesting some active renal excretion.<br />Time-dependency<br />Total exposure (AUC(0-inf)) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC(0-24)) after 6 days of once daily dosing. This indicates no time-dependency in the kinetics of alogliptin after multiple dosing.<br />Special populations<br />Renal impairment<br />A single dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (creatinine clearance (CrCl) using the Cockcroft-Gault formula):<br />mild (CrCl = &gt; 50 to &le; 80 mL/min), moderate (CrCl = &ge; 30 to &le; 50 mL/min), severe (CrCl = &lt; 30 mL/min) and end-stage renal disease on haemodialysis.<br />An approximate 1.7-fold increase in AUC for alogliptin was observed in patients with mild renal impairment. However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment of alogliptin for patients with mild renal impairment is necessary (see section 4.2).</p><p>In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing. Based on mean dialysate concentrations, approximately 7% of the drug was removed during a 3-hour haemodialysis session.) Therefore, in order to maintain systemic exposures to alogliptin that are&nbsp;similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see above and section 4.2).<br />Hepatic impairment<br />Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to control subjects. The magnitude of these reductions was not considered to be clinically relevant. Therefore, no dose adjustment of alogliptin is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores<br />of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9).<br />Age, gender, race, body weight<br />Age (65-81 years old), gender, race (white, black and Asian) and body weight did not have any clinically relevant effect on the pharmacokinetics of alogliptin. No dose adjustment is necessary (see section 4.2).<br />Paediatric population<br />The pharmacokinetics of alogliptin in children and adolescents &lt; 18 years old has not been established. No data are available (see section 4.2 and above).<br />Metformin<br />Absorption<br />After an oral dose&nbsp;of metformin, the maximum plasma concentration (Cmax) is reached in approximately 2.5 hours (Tmax). Absolute bioavailability of a 500 mg or 850 mg metformin hydrochloride tablet is approximately 50-60% in healthy subjects. After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.<br />After oral administration, metformin absorption is saturable and incomplete. It is assumed that the pharmacokinetics of metformin absorption is non-linear.<br />At the recommended metformin doses and dosing schedules, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally less than 1 microgram/mL. In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 4 microgram/mL even at maximum doses.<br />Food slightly delays and decreases the extent of the absorption of metformin. Following oral administration of an 850 mg metformin hydrochloride tablet, the peak plasma concentration was 40% lower, AUC was decreased by 25% and the time to peak plasma concentration (Tmax) was prolonged by 35 minutes. The clinical relevance of these findings is unknown.<br />Distribution<br />Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution (Vd) ranged between 63-276 L.</p><p>Biotransformation<br />Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.</p><p>Elimination<br />Renal clearance of metformin is &gt; 400 mL/min indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.<br />When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and, thus, the elimination half-life is prolonged leading to increased levels of metformin in the plasma.<br />Zytero Plus<br />Special populations<br />Renal impairment<br />Due to its metformin component, Zytero Plus should not be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see section 4.2).<br />Hepatic impairment<br />Zytero Plus should not be used in patients with hepatic impairment (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant treatment with alogliptin and metformin did not produce new toxicities and no effects on the toxicokinetics of either compound were observed.<br />In rats no treatment-related foetal abnormalities occurred following concomitant administration at exposure margins of approximately 28- to 29-fold for alogliptin and 2- to 2.5-fold for metformin at the maximum recommended human dose of 25 mg/day and 2000 mg/day, respectively. The combination revealed teratogenic potential in small numbers of foetuses (microphthalmia, small eye bulge and cleft palate) at higher doses of metformin (exposure margins of approximately 20-fold and 5- to 6-fold the maximum recommended human dose for alogliptin and metformin, respectively).<br />The following data are findings from studies performed with alogliptin or metformin individually. Alogliptin<br />Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and toxicology.<br />The no-observed-adverse-effect level (NOAEL) in the repeated dose toxicity studies in rats and dogs up to 26- and 39-weeks in duration, respectively, produced exposure margins that were approximately 147- and 227-fold, respectively, the exposure in humans at the recommended total daily dose of 25 mg alogliptin.<br />Alogliptin was not genotoxic in a standard battery of in vitro and in vivo genotoxicity studies.</p><p>Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice. Minimal to mild simple transitional cell hyperplasia was seen in the urinary bladder of male rats at the lowest dose used (27 times the human exposure) without establishment of a clear NOEL (no observed effect level).<br />No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose. Although fertility was not affected, a slight, statistical increase in the number of abnormal sperm was observed in males at an exposure far above the human exposure at the recommended dose.</p><p>Placental transfer of alogliptin occurs in rats.<br />Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose. Higher doses of alogliptin were not teratogenic but resulted in maternal toxicity, and were associated with delayed and/or lack of ossification of bones and decreased foetal body weights.<br />In a pre- and postnatal development study in rats, exposures far above the human exposure at the recommended dose did not harm the developing embryo or affect offspring growth and development. Higher doses of alogliptin decreased offspring body weight and exerted some developmental effects considered secondary to the low body weight.<br />Studies in lactating rats indicate that alogliptin is excreted in milk.<br />No alogliptin-related effects were observed in juvenile rats following repeat-dose administration for 4 and 8 weeks.<br />Metformin<br />Preclinical data for metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol Microcrystalline cellulose Povidone<br />Crospovidone Magnesium stearate<br />The tablets are film-coated with hypromellose 2910 Talc<br />Titanium dioxide Ferric oxide yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary Packaging Material: The packaging configuration for blister packs is constructed of aluminum forming material and aluminum lidding material.<br />Secondary Packaging Material: Carton.<br />Pack sizes of 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 196 (2x98 multipack) or 200 film-coated tablets.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batterjee pharmaceutical factory Industrial Area-phase-IV,
Jeddah-21443, Kingdom of Saudi
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>